Startek Offers Mental Health Support App to New Mothers as Part of Diversity, Equity and Inclusion Initiatives

MamaLift Postpartum Mental Health Support Program Made Available to U.S.-Based Postpartum Associates DENVER–(BUSINESS WIRE)–Startek® (NYSE: SRT), a global customer experience (CX) solutions provider, today announced that it has partnered with Curio Digital Therapeutics to offer postpartum mental health support for its U.S.-based associates as part of its ongoing initiatives designed to promote diversity, equity and … [Read more…]

Caraway Therapeutics to Present at the 33rd Annual Oppenheimer Healthcare Conference

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Caraway Therapeutics today announced that the Company will be participating in the 33rd Annual Oppenheimer Healthcare Conference on March 13, 2023. Caraway’s Chief Executive Officer, Martin D. Williams, will present recent advances in the Company’s TRPML1 programs from 4:40pm-5:10pm ET. In addition, the Company will be participating in 1-on-1 investor meetings during the … [Read more…]

Astria Therapeutics to Report Fourth Quarter/Full Year 2022 Financial Results and Recent Corporate Developments on Wednesday, March 22nd

BOSTON–(BUSINESS WIRE)–Astria Therapeutics, Inc. (NASDAQ:ATXS) a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE) and focused on life-changing therapies for rare and niche allergic and immunological diseases, will report fourth quarter/full year 2022 financial results before the Nasdaq Global Market open on Wednesday, March 22, 2023. Jill C. Milne, Ph.D., Chief Executive … [Read more…]

Lantern Pharma to Host Virtual KOL Webinar on Synthetic Lethality, the Powerful Mechanism of Action Behind Several of Lantern’s Drug Candidates, Featuring Zoltan Szallasi, M.D.

Webinar to be hosted on Tuesday, March 21, 2023 at 12:00 p.m. ET, register here, or at the link below. Dr. Zoltan Szallasi will provide a high-level overview of synthetic lethality, why synthetic lethality has become a desired trait for drugs in oncology, and an in-depth look at how Lantern is leveraging the synthetic lethality … [Read more…]

FitReserve Expands Premier Studio Network to More Major Markets

— FitReserve Now Available in San Francisco, Miami, Fort Lauderdale, West Palm Beach, Dallas, Denver, San Diego, Tampa, Seattle, and Charlotte — LAKE FOREST, Ill.–(BUSINESS WIRE)–FitReserve, a multi-studio fitness membership that allows members to mix and match in-person, live-stream, and on-demand workouts, today announced its launch in 10 more markets: San Francisco, Miami, Fort Lauderdale, … [Read more…]

Recommendations by Expert Consensus Panel Relating to Risk-Stratification Tests and Tools for Use in Cutaneous Melanoma Have Been Adopted as an Official Policy Recommendation of the National Society for Cutaneous Medicine

Report states that DecisionDx®-Melanoma offers more utility than other existing GEP assays or nomograms, supported by extensive evidence-driven data for the test in current literature Report includes 10 additional usage guidelines and consensus supporting statements for incorporating GEP testing, including DecisionDx-Melanoma, into clinical practice to improve care for patients with cutaneous melanoma FRIENDSWOOD, Texas–(BUSINESS WIRE)–$CSTL … [Read more…]

Alnylam Announces Appointment of Peter Kellogg to Board of Directors

– Experienced Business and Financial Leader, Kellogg Served as Chief Financial Officer at Biogen, Merck, and Celgene – CAMBRIDGE, Mass.–(BUSINESS WIRE)–Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) the leading RNAi therapeutics company, announced today the appointment of Peter Kellogg to its Board of Directors. Mr. Kellogg is an accomplished industry executive with extensive global financial and strategic … [Read more…]

VarmX Appoints Dr. Jeffrey Lawson, MD, PhD as Chief Scientific Officer

Prof. Dr. Pieter Reitsma, former CSO and founder, to continue as Special Advisor to VarmX management & Board LEIDEN, The Netherlands–(BUSINESS WIRE)–VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces the appointment of Dr. Jeffrey Lawson as its new Chief Scientific Officer (CSO). Dr. Lawson will … [Read more…]

Diversey to be Acquired by Solenis for $4.6 Billion

Diversey Public Shareholders to Receive $8.40 Per Share in Cash in “Go Private” Transaction Combined company will allow for expanded markets and additional sustainable solutions WILMINGTON, Del. & FORT MILL, S.C.–(BUSINESS WIRE)–Solenis (“Solenis”) and Diversey Holdings, Ltd. (“Diversey” or the “Company”) (NASDAQ: DSEY) today announced they have entered into a definitive merger agreement under which … [Read more…]

Merck to Present at the Barclays 2023 Global Healthcare Conference

RAHWAY, N.J.–(BUSINESS WIRE)–$MRK #MRK–Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Jannie Oosthuizen, president, Human Health U.S., is scheduled to participate in a fireside chat at the Barclays 2023 Global Healthcare Conference on Wednesday, March 15, 2023, at 2:35 p.m. ET. Investors, analysts, members of the media … [Read more…]